Quick answers
- What is Neomycin sulfate and fluocinolone acetonide used for?
- The FDA-approved label (Neo-Synalar, Eurofarma, Inc., March 18, 2026) says: “NEO-SYNALAR ® cream is indicated for the treatment of corticosteroid-responsive dermatoses with secondary infection. It has not been demonstrated that this steroid-antibiotic combination provides greater benefit than the steroid component alone after 7 days of treatment (see WARNINGS section).” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- What are the side effects of Neomycin sulfate and fluocinolone acetonide?
- The “Adverse Reactions” section of the FDA label (Neo-Synalar, Eurofarma, Inc., March 18, 2026) begins: “The following local adverse reactions are reported infrequently with topical corticosteroids.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Neomycin sulfate and fluocinolone acetonide have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Neomycin sulfate and fluocinolone acetonide?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
- Has Neomycin sulfate and fluocinolone acetonide been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Neomycin sulfate and fluocinolone acetonide?
- 1 company lists prescription products of Neomycin sulfate and fluocinolone acetonide in the FDA NDC Directory, including Eurofarma, Inc.
What Neomycin sulfate and fluocinolone acetonide is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
NEO-SYNALAR ® cream is indicated for the treatment of corticosteroid-responsive dermatoses with secondary infection. It has not been demonstrated that this steroid-antibiotic combination provides greater benefit than the steroid component alone after 7 days of treatment (see WARNINGS section).
— FDA label: Neo-Synalar, Eurofarma, Inc., effective March 18, 2026. Read the full label on DailyMed →
Label quoted: the one for the most common form (cream, topical), Neo-Synalar, Eurofarma, Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Neomycin sulfate and fluocinolone acetonide side effects
Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.
The following local adverse reactions are reported infrequently with topical corticosteroids.
Read more of this section
These reactions are listed in an approximate decreasing order of occurrence: Burning Hypertrichosis Maceration of the skin Itching Acneiform eruptions Secondary infection Irritation Hypopigmentation Skin atrophy Dryness Perioral dermatitis Striae Folliculitis Allergic contact dermatitis Miliaria The following adverse reactions have been reported with the topical use of neomycin: Ototoxicity Nephrotoxicity
Table from the label
| Burning | Hypertrichosis | Maceration of the skin |
|---|---|---|
| Itching | Acneiform eruptions | Secondary infection |
| Irritation | Hypopigmentation | Skin atrophy |
| Dryness | Perioral dermatitis | Striae |
| Folliculitis | Allergic contact dermatitis | Miliaria |
— FDA label: Neo-Synalar, Eurofarma, Inc., effective March 18, 2026. This is part of the section. Read the full label on DailyMed →
Neomycin sulfate and fluocinolone acetonide dosage
Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.
NEO-SYNALAR ® cream is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. Since NEO-SYNALAR ® cream is a water-washable vanishing cream, it is easily applied and leaves no traces.
— FDA label: Neo-Synalar, Eurofarma, Inc., effective March 18, 2026. Read the full label on DailyMed →
Neomycin sulfate and fluocinolone acetonide in pregnancy
Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.
Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids.
Read more of this section
Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
— FDA label: Neo-Synalar, Eurofarma, Inc., effective March 18, 2026. Read the full label on DailyMed →
Neomycin sulfate and fluocinolone acetonide and breastfeeding
Quoted from the nursing mothers / lactation part of the FDA-approved label.
It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.
— FDA label: Neo-Synalar, Eurofarma, Inc., effective March 18, 2026. Read the full label on DailyMed →
When Neomycin sulfate and fluocinolone acetonide should not be used
Quoted from the “Contraindications” section of the FDA-approved label.
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. This product should not be used in the external auditory canal if the eardrum is perforated.
— FDA label: Neo-Synalar, Eurofarma, Inc., effective March 18, 2026. Read the full label on DailyMed →
Neomycin sulfate and fluocinolone acetonide overdose
Quoted from the “Overdosage” section of the FDA-approved label. If someone may have taken too much, call Poison Help at 1-800-222-1222 (or 911 in an emergency).
Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS).
— FDA label: Neo-Synalar, Eurofarma, Inc., effective March 18, 2026. Read the full label on DailyMed →
Forms and how it is given
| Dosage forms | Cream |
|---|---|
| Route | Topical |
| Prescription products | 1 in the FDA NDC Directory |
| Brand names | Neo-Synalar |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Eurofarma, Inc.1 product
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (1)
- ANDA060700Eurofarma · June 11, 1963
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| RxCUI (RxNorm) | 1191359, 1542994 |
|---|---|
| SPL set ID of the quoted label | 1141956e-8a4c-4f80-95d1-f15bdb57fdf6 |
| FDA labels (SPL) | 1 |
| FDA applications | 1 ANDA |
| Active ingredients (FDA) | FLUOCINOLONE ACETONIDE / NEOMYCIN SULFATE |
Next steps
- Find a pharmacy near youAsk which price applies to you and whether your product is affected by a recall
- Latest FDA drug recallsAll medicines, newest first
- Eurofarma, Inc.Maker or distributor
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Neo-Synalar, Eurofarma, Inc., effective March 18, 2026; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →